CompletedPhase 2NCT05964335
Cough Reduction in IPF With Nalbuphine ER
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Trevi Therapeutics
- Principal Investigator
- Chief Development OfficerTrevi Therapeutics
- Intervention
- NAL ER(drug)
- Enrollment
- 165 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2025
Study locations (30)
- Eastern Health-Box Hill Hospital, Box Hill, Australia
- Concord Repatriation General Hospital, Concord, Australia
- Austin Hospital, Heidelberg, Australia
- Respiratory Clinical Trials Pty Ltd, Kent Town, Australia
- TrialsWest Pty Ltd, Spearwood, Australia
- Westmead Hospital, Westmead, Australia
- CIC Mauricie Inc., Trois-Rivières, Quebec, Canada
- Dynamic Drug Advancement, Ajax, Canada
- Centre for Lung Health Clinic, Vancouver, Canada
- The Pacific Lung Health Centre - St. Pauls Hospital, Vancouver, Canada
- Hospital Clinico Regional Dr. Guillermo Grant Benavente, Concepción, Chile
- Centro de Investigaciones Medicas Cemedin Ltda., Quillota, Chile
- Clinica Universidad de los Andes, Santiago, Chile
- Centro de Investigacion del Maule, Talca, Chile
- Hospital Carlos Van Buren, Valparaíso, Chile
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05964335 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics